These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 29309998)

  • 1. Drugs which influence serotonin transporter and serotonergic receptors: Pharmacological and clinical properties in the treatment of depression.
    Taciak PP; Lysenko N; Mazurek AP
    Pharmacol Rep; 2018 Feb; 70(1):37-46. PubMed ID: 29309998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of melatonergic and non-melatonergic antidepressants on sleep: weighing the alternatives.
    Pandi-Perumal SR; Trakht I; Srinivasan V; Spence DW; Poeggeler B; Hardeland R; Cardinali DP
    World J Biol Psychiatry; 2009; 10(4 Pt 2):342-54. PubMed ID: 18609422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serotonergic drugs for depression and beyond.
    Stahl SM; Lee-Zimmerman C; Cartwright S; Morrissette DA
    Curr Drug Targets; 2013 May; 14(5):578-85. PubMed ID: 23531115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy of atypical antipsychotics in depressive syndromes].
    Quintin P; Thomas P
    Encephale; 2004; 30(6):583-9. PubMed ID: 15738862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Other Antidepressants.
    Schwasinger-Schmidt TE; Macaluso M
    Handb Exp Pharmacol; 2019; 250():325-355. PubMed ID: 30194544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered γ-aminobutyric acid neurotransmission in major depressive disorder: a critical review of the supporting evidence and the influence of serotonergic antidepressants.
    Pehrson AL; Sanchez C
    Drug Des Devel Ther; 2015; 9():603-24. PubMed ID: 25653499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoamine neurocircuitry in depression and strategies for new treatments.
    Hamon M; Blier P
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Aug; 45():54-63. PubMed ID: 23602950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vortioxetine: a New Treatment for Major Depressive Disorder.
    Connolly KR; Thase ME
    Expert Opin Pharmacother; 2016; 17(3):421-31. PubMed ID: 26679430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using acute tryptophan depletion to investigate predictors of treatment response in adolescents with major depressive disorder: study protocol for a randomised controlled trial.
    Stewart RM; Hood SD; Rao P; Moore JK; Runions KC; Murphy SE; Wong JWY; Zepf FD
    Trials; 2018 Aug; 19(1):434. PubMed ID: 30097056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Antidepressant and tolerance: Determinants and management of major side effects].
    David DJ; Gourion D
    Encephale; 2016 Dec; 42(6):553-561. PubMed ID: 27423475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs.
    Millan MJ
    Neurotherapeutics; 2009 Jan; 6(1):53-77. PubMed ID: 19110199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulating the serotonin system in the treatment of major depressive disorder.
    Morrissette DA; Stahl SM
    CNS Spectr; 2014 Dec; 19 Suppl 1():57-67; quiz 54-7, 68. PubMed ID: 25544378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Major depressive disorder, antidepressants and sexual dysfunction].
    Kinzl JF
    Neuropsychiatr; 2009; 23(2):134-8. PubMed ID: 19573505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of major depression: selection of initial drug.
    Potter WZ; Schmidt ME
    Mod Probl Pharmacopsychiatry; 1997; 25():1-16. PubMed ID: 9344366
    [No Abstract]   [Full Text] [Related]  

  • 15. Adolescent angst or true intent? Suicidal behavior, risk, and neurobiological mechanisms in depressed children and teenagers taking antidepressants.
    Morrison J; Schwartz TL
    Int J Emerg Ment Health; 2014; 16(1):247-50. PubMed ID: 25345238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of agomelatine and selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors in major depressive disorder: A meta-analysis of head-to-head randomized clinical trials.
    Huang KL; Lu WC; Wang YY; Hu GC; Lu CH; Lee WY; Hsu CC
    Aust N Z J Psychiatry; 2014 Jul; 48(7):663-71. PubMed ID: 24604920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Limitations of contemporary antidepressants: tolerability.
    Papakostas GI
    J Clin Psychiatry; 2007; 68 Suppl 10():11-7. PubMed ID: 17900204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Revisiting serotonin reuptake inhibitors and the therapeutic potential of "uptake-2" in psychiatric disorders.
    Daws LC; Koek W; Mitchell NC
    ACS Chem Neurosci; 2013 Jan; 4(1):16-21. PubMed ID: 23336039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vilazodone, a novel dual-acting serotonergic antidepressant for managing major depression.
    Khan A
    Expert Opin Investig Drugs; 2009 Nov; 18(11):1753-64. PubMed ID: 19764890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective serotonin reuptake inhibitors in children and adolescents with major depression.
    Scahill L
    Braz J Psychiatry; 2005 Jun; 27(2):91-2. PubMed ID: 15962129
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.